IL252882B - History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists - Google Patents

History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists

Info

Publication number
IL252882B
IL252882B IL252882A IL25288217A IL252882B IL 252882 B IL252882 B IL 252882B IL 252882 A IL252882 A IL 252882A IL 25288217 A IL25288217 A IL 25288217A IL 252882 B IL252882 B IL 252882B
Authority
IL
Israel
Prior art keywords
rarbeta
bicycloheteroaryl
agonists
heteroaryl
receptor beta
Prior art date
Application number
IL252882A
Other languages
English (en)
Hebrew (he)
Other versions
IL252882A0 (en
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of IL252882A0 publication Critical patent/IL252882A0/en
Publication of IL252882B publication Critical patent/IL252882B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL252882A 2014-12-17 2017-06-13 History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists IL252882B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201422472 2014-12-17
PCT/EP2015/080029 WO2016097004A1 (en) 2014-12-17 2015-12-16 BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS

Publications (2)

Publication Number Publication Date
IL252882A0 IL252882A0 (en) 2017-08-31
IL252882B true IL252882B (en) 2020-04-30

Family

ID=55027725

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252882A IL252882B (en) 2014-12-17 2017-06-13 History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists

Country Status (11)

Country Link
US (4) US9994559B2 (enExample)
EP (1) EP3233842B1 (enExample)
JP (1) JP6596090B2 (enExample)
KR (1) KR102526625B1 (enExample)
CN (1) CN107207488B (enExample)
AU (1) AU2015367531B2 (enExample)
BR (1) BR112017012588B8 (enExample)
CA (1) CA2970574C (enExample)
ES (1) ES3029609T3 (enExample)
IL (1) IL252882B (enExample)
WO (1) WO2016097004A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233842B1 (en) * 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
GB201610867D0 (en) * 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN111892591A (zh) * 2019-05-06 2020-11-06 南京科技职业学院 一种维奈托克关键中间体的合成方法
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
CN115427401B (zh) 2020-05-29 2025-04-11 巴斯夫欧洲公司 取代4-(n′-羟基甲脒基)苯甲酸的制备
CN112552252B (zh) * 2020-09-30 2024-01-02 浙江美诺华药物化学有限公司 一种氟雷拉纳中间体的制备方法
CN113264832A (zh) * 2021-05-13 2021-08-17 南京爱可德夫科技开发有限公司 一种合成高纯度2-氟-4-溴苯甲酸叔丁酯的方法
CN116640071B (zh) * 2023-05-04 2024-08-30 四川青木制药有限公司 一种制备2-甲基4-甲醛肟基苯甲酸及其酯类衍生物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709475A (es) 1995-06-07 1998-02-28 Nippon Shinyaku Co Ltd Derivados de pirrol y composicion medicinal.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CN1211361C (zh) 1996-03-18 2005-07-20 卫材株式会社 含有稠环的羧酸衍生物
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US6355669B1 (en) 1997-10-22 2002-03-12 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
JP2000154150A (ja) * 1997-10-22 2000-06-06 Eisai Co Ltd 腎炎予防・治療剤としてのレチノイン酸アゴニスト
RU2241709C2 (ru) * 1999-07-09 2004-12-10 Орто-Макнейл Фармасьютикал, Инк. Производные азотсодержащих гетероциклических соединений и способ лечения расстройств, характеризующихся поражением нейронов
US20020048580A1 (en) * 2000-06-07 2002-04-25 Institut National De La Sante Et De La Recherche Medicale Method of inducing lung branching
CA2449544A1 (en) 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
WO2003062230A1 (en) * 2002-01-21 2003-07-31 Eisai Co., Ltd. Conbinatorial library of heterocycle compounds
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
PL2910551T3 (pl) 2003-04-11 2017-09-29 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
MX2007004479A (es) * 2004-10-13 2007-06-18 Ptc Therapeutics Inc Compuestoss para supresion sin sentido y metodos para su uso.
US20090176837A1 (en) 2005-07-12 2009-07-09 Sony Corporation Compounds with activity at retinoic acid receptors
EP2304366A2 (en) 2008-05-30 2011-04-06 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
GB0915196D0 (en) * 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3233842B1 (en) * 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists

Also Published As

Publication number Publication date
US10385044B2 (en) 2019-08-20
US20200131165A1 (en) 2020-04-30
US20210130337A1 (en) 2021-05-06
CA2970574C (en) 2023-09-19
EP3233842B1 (en) 2025-03-26
EP3233842C0 (en) 2025-03-26
CN107207488A (zh) 2017-09-26
US11401265B2 (en) 2022-08-02
AU2015367531B2 (en) 2020-04-30
KR102526625B1 (ko) 2023-04-27
IL252882A0 (en) 2017-08-31
CA2970574A1 (en) 2016-06-23
US10752616B2 (en) 2020-08-25
ES3029609T3 (en) 2025-06-24
CN107207488B (zh) 2020-11-17
JP2017537967A (ja) 2017-12-21
BR112017012588A2 (pt) 2018-11-13
EP3233842A1 (en) 2017-10-25
US9994559B2 (en) 2018-06-12
BR112017012588B1 (pt) 2023-11-07
US20190010146A1 (en) 2019-01-10
WO2016097004A1 (en) 2016-06-23
BR112017012588B8 (pt) 2024-02-15
AU2015367531A1 (en) 2017-07-06
KR20170097125A (ko) 2017-08-25
US20170327489A1 (en) 2017-11-16
JP6596090B2 (ja) 2019-10-23

Similar Documents

Publication Publication Date Title
ZA201802371B (en) Glucagon receptor agonists
IL252257A0 (en) Insulin receptor partial agonists
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
IL252882B (en) History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists
ZA201703007B (en) Boronic acid derivatives
EP3194429A4 (en) Novel feline erythropoietin receptor agonists
SG11201702625PA (en) Boronic acid derivatives
ZA201604527B (en) Compounds for use as gpr120 agonists
SG11201702623TA (en) Boronic acid derivatives
IL246655B (en) A medical preparation containing a pyridyl amino acetic acid compound
ZA201607638B (en) Compositions for removable labels
EP3166923A4 (en) Process for preparing substituted phenylalkanes
ZA201605102B (en) Substituted bicyclic heteroaryl compounds as rxr agonists
EP3094380A4 (en) Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
EP3218721A4 (en) Compounds for use as imaging agents
PT3453694T (pt) Biofertilizante para aumentar o rendimento das culturas
EP3105207A4 (en) Gpr142 agonist compounds
IL243730A0 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists
HK1236210A1 (en) Insulin receptor partial agonists
GB201520189D0 (en) Compound for use
GB201416462D0 (en) Compound for use
GB201408759D0 (en) Compound for use
PL2898768T3 (pl) System karmienia prosiąt
GB201400386D0 (en) Agonists

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed